A provider-focused update on Fluticasone/Vilanterol (Breo Ellipta) supply in 2026, including prescribing implications, alternatives, and patient tools.
If your patients have been reporting difficulty filling their Fluticasone/Vilanterol (Breo Ellipta) prescriptions, you're not alone in hearing it. While this ICS/LABA combination inhaler hasn't been placed on the FDA's formal drug shortage list, intermittent retail-level stock-outs have been a recurring issue across multiple regions.
This briefing covers the current supply picture, prescribing considerations, cost and access challenges, and tools you can share with patients to help them locate this medication.
Fluticasone Furoate/Vilanterol was FDA-approved in 2013 for COPD and subsequently approved for asthma maintenance in adults in 2017. Manufactured by GlaxoSmithKline (GSK), the Ellipta device platform has been broadly adopted due to its once-daily dosing convenience and intuitive inhaler design.
Key milestones relevant to supply:
For providers managing patients on Fluticasone/Vilanterol, the intermittent availability issues create several practical challenges:
Patients who miss doses of their maintenance ICS/LABA are at increased risk of exacerbations. When a pharmacy can't fill the prescription promptly, patients may go days without their controller medication. This is particularly concerning for patients with moderate-to-severe asthma or frequent COPD exacerbations.
When Fluticasone/Vilanterol is unavailable, the most common substitutions include:
When substituting, consider:
For COPD patients who have been on Fluticasone/Vilanterol, consider whether a step-up to triple therapy is clinically appropriate. Options include:
The supply situation for Fluticasone/Vilanterol in 2026 can be characterized as:
Cost remains a significant barrier for many patients:
For uninsured or underinsured patients, the GSK Patient Assistance Program provides Breo Ellipta at no cost for qualifying patients (generally household income ≤300% FPL). Applications available at GSKForYou.com.
For a patient-facing cost guide to share, see: How to Save Money on Fluticasone/Vilanterol in 2026.
Several tools can help your practice and your patients navigate availability challenges:
Medfinder for Providers helps clinicians and care teams check real-time pharmacy stock for medications like Fluticasone/Vilanterol. You can direct patients to the tool or use it within your workflow to identify pharmacies that have the medication in stock before writing the prescription.
Share these resources with patients who are having difficulty:
The respiratory medication landscape continues to evolve. Key developments to watch in 2026 and beyond:
Fluticasone/Vilanterol remains an effective and well-tolerated option for asthma and COPD maintenance therapy. While there is no formal shortage, the intermittent availability issues are real and affect patient adherence. By staying informed about alternatives, leveraging tools like Medfinder for Providers, and proactively communicating with patients about refill strategies, you can help minimize disruptions to care.
For a practical workflow guide, see our companion post: How to Help Your Patients Find Fluticasone/Vilanterol in Stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
